Risk-adapted Therapeutic Strategy in +1q NDMM
ConditionMultiple Myeloma
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorFengYan Jin
About this trial
This real-world, multicenter prospective clinical study is designed to apply our internationally developed prognostic scoring system to guide individualized therapy in +1q newly diagnosed multiple myeloma (NDMM), using minimal residual disease (MRD) status as the primary endpoint.
Eligibility criteria
Qualifiers
Age >=18, or >=65 and fit according to IMWG-FI.
Newly diagnosed NDMM by 2014 IMWG criteria.
Adequate organ function for systemic therapy.
Signed informed consent.
Disqualifiers
Active infections requiring systemic treatment.
Unstable angina, NYHA class III-IV heart failure, or uncontrolled arrhythmias.
History of hematologic or solid tumors treated with chemo/radiotherapy within 5 years.
Current malignancies requiring therapy.
Trial design
Treatments tested in this trial
- risk-scoring model
Treatment groups
200 Participants
are divided into 4 treatment groupsSponsors and collaborators
FengYan Jin
Lead sponsor
The First Hospital of Jilin University
Sponsor institution
Source ClinicalTrials.gov